Molecular Assays

PCR assays enable minimally invasive, repeatable analysis of genetic and transcriptomic biomarkers on CTCs isolated using the Parsortix Platform. Customers can access workflows for reverse transcription PCR (qRT-PCR) and digital PCR (dPCR). Results include mutation detection, copy number changes, or gene expression profiles from captured CTCs.

How Can CelLBxHealth’s PCR Workflows Support Your Clinical Trial?

• Enable minimally invasive liquid biopsy assessment of mutations and gene expression from intact CTCs
• Support patient stratification and early identification of resistance mechanisms
• Allow longitudinal monitoring of treatment response and tumor evolution
• Provide highly sensitive and reproducible results, even from low CTC numbers

CTCs are emerging to provide additional and complementary gene variant data compared to circulating tumor DNA (ctDNA) alone

A dual analysis approach has the potential to make substantive improvements in patient care.

CelLBxHealth has developed a single blood tube, next-generation sequencing (NGS) workflow that enables highly sensitive dual analysis of CTC-DNA and cell-free DNA (cfDNA, which includes ctDNA) across a large gene panel.

By integrating this DNA dual analysis workflow, CelLBxHealth aims to advance research-use applications to provide deeper insights into cancer biology through liquid biopsy analysis.

DNA dual analysis has the potential to identify a broader range of clinically actionable biomarkers, which could help the clinician track tumor evolution to inform treatment decisions, monitor response to treatment, identify drug resistance mechanisms and identify disease progression earlier^1-6.